{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:27:56Z","timestamp":1792787276348,"version":"4.5.0"},"reference-count":49,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"unspecified","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GSK"},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["224485\/Z\/21\/Z"],"award-info":[{"award-number":["224485\/Z\/21\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","award":["[MR\/S017968\/1]"],"award-info":[{"award-number":["[MR\/S017968\/1]"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","award":["[MR\/T041285\/1]"],"award-info":[{"award-number":["[MR\/T041285\/1]"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,10,2]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Observational data are increasingly used to study and draw causal inferences about the effects of treatments. Target trial emulation (TTE) is a framework for mitigating biases in causal investigations through specification of an observational study, targeting a specific causal research question, based on a real or hypothetical randomised controlled trial. Investigations into the effects of treatment discontinuation are of growing interest and particularly relevant in cystic fibrosis (CF), where treatment burden is high and new transformative therapies are becoming widespread. We aim to use the TTE framework to investigate the effect of discontinuation of inhaled corticosteroids (ICS) on clinical outcomes in people with CF. Our observational emulation will be based on the CF WISE (Withdrawal of Inhaled Steroids Evaluation) trial (PMID:16556691).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>Two study designs proposed for investigating treatment effects using observational data are the prevalent new-user design and the sequential trials design. Each design uses different but related methods to address similar causal questions; however, the comparability between them remains uncertain. We will conduct a population-based cohort study using data from the UK CF Registry between January 2016 and June 2018 and apply these designs. We will specify the target trial protocol for each study design. Estimates for the causal effects of discontinuing ICS will be obtained and compared with those from the CF-WISE trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study has received approval from the UK CF Registry Research Committee for both the research and access to data. Ethical approval has also been granted by the LSHTM Ethics Committee. The UK CF Registry has NHS Research Ethics Committee approval (REC reference: 24\/EE\/0012). The findings from this project will be submitted to peer-reviewed journals and presented at academic conferences.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-100894","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T17:27:24Z","timestamp":1761758844000},"page":"e100894","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of deprescribing from inhaled corticosteroids in people with cystic fibrosis: protocol for a target trial emulation using the UK CF Registry"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0902-6122","authenticated-orcid":false,"given":"Elliot","family":"McClenaghan","sequence":"first","affiliation":[{"name":"Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Rouette","sequence":"additional","affiliation":[{"name":"Global Epidemiology, Office of the Chief Medical Officer GSK R&D, GlaxoSmithKline Plc, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0134-1467","authenticated-orcid":false,"given":"Emily","family":"Granger","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwyneth","family":"Davies","sequence":"additional","affiliation":[{"name":"Population Policy and Practice Research and Teaching Department, University College London Great Ormond Street Institute of Child Health, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth H","family":"Keogh","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7194-2615","authenticated-orcid":false,"given":"John","family":"Tazare","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"2025120415090434000_15.10.e100894.1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv254"},{"key":"2025120415090434000_15.10.e100894.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0597-x"},{"key":"2025120415090434000_15.10.e100894.3","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/EDE.0b013e3181875e61","article-title":"Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease","volume":"19","author":"Hern\u00e1n","year":"2008","journal-title":"Epidemiology (Sunnyvale)"},{"key":"2025120415090434000_15.10.e100894.4","first-page":"2049","article-title":"Commentary: Should the analysis of observational data always be preceded by specifying a target experimental trial?","volume":"45","author":"Didelez","year":"2016","journal-title":"Int J Epidemiol"},{"key":"2025120415090434000_15.10.e100894.5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.36023","article-title":"Reporting of Observational Studies Explicitly Aiming to Emulate Randomized Trials: A Systematic Review","volume":"6","author":"Hansford","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025120415090434000_15.10.e100894.6","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00170-2022","article-title":"The long-term effects of insulin use in incident cystic fibrosis-related diabetes: a target trial emulated using longitudinal national registry data","volume":"8","author":"Granger","year":"2022","journal-title":"ERJ Open Res"},{"key":"2025120415090434000_15.10.e100894.7","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2023-220031"},{"key":"2025120415090434000_15.10.e100894.8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025120415090434000_15.10.e100894.9","unstructured":"UK Cystic Fibrosis Registry . 2022 annual data report. 2023. Available: https:\/\/www.cysticfibrosis.org.uk\/about-us\/uk-cf-registry\/reporting-and-resources"},{"key":"2025120415090434000_15.10.e100894.10","doi-asserted-by":"crossref","DOI":"10.3310\/nihropenres.13260.1","article-title":"Exploring the nature of perceived treatment burden: a study to compare treatment burden measures in adults with cystic fibrosis [version 1; peer review: 2 approved]","volume":"2","author":"Altabee","year":"2022","journal-title":"NIHR Open Res"},{"key":"2025120415090434000_15.10.e100894.11","article-title":"Inhaled corticosteroids for cystic fibrosis","volume":"7","author":"Balfour-Lynn","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2025120415090434000_15.10.e100894.12","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200511-1808OC"},{"key":"2025120415090434000_15.10.e100894.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"2025120415090434000_15.10.e100894.14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/pds.5507","article-title":"HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: A good practices report of a joint ISPE\/ISPOR task force","volume":"32","author":"Wang","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025120415090434000_15.10.e100894.15","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyx196"},{"key":"2025120415090434000_15.10.e100894.16","unstructured":"NICE real-world evidence framework. 2022. Available: https:\/\/www.nice.org.uk\/corporate\/ecd9\/chapter\/introduction-to-real-world-evidence-in-nice-decision-making [Accessed 24 Oct 2025]."},{"key":"2025120415090434000_15.10.e100894.17","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4107"},{"key":"2025120415090434000_15.10.e100894.18","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/pds.5656","article-title":"Prevalent new user designs: A literature review of current implementation practice","volume":"32","author":"Tazare","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025120415090434000_15.10.e100894.19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/15412555.2022.2045265","article-title":"Discontinuation of Inhaled Corticosteroids from Triple Therapy in COPD: Effects on Major Outcomes in Real World Clinical Practice","volume":"19","author":"Suissa","year":"2022","journal-title":"COPD"},{"key":"2025120415090434000_15.10.e100894.20","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000001628"},{"key":"2025120415090434000_15.10.e100894.21","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/sim.9718","article-title":"Causal inference in survival analysis using longitudinal observational data: Sequential trials and marginal structural models","volume":"42","author":"Keogh","year":"2023","journal-title":"Stat Med"},{"key":"2025120415090434000_15.10.e100894.22","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4048"},{"key":"2025120415090434000_15.10.e100894.23","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.arbres.2021.12.003","article-title":"The Impact of COVID-19 in Cystic Fibrosis","volume":"58","author":"Flume","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"2025120415090434000_15.10.e100894.24","unstructured":"Hern\u00e1n MA , Robins JM . Causal inference: What if. Chapman & Hall\/CRC, 2020."},{"key":"2025120415090434000_15.10.e100894.25","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2024-002456","article-title":"Definitions of pulmonary exacerbation in people with cystic fibrosis: a scoping review","volume":"11","author":"Almulhem","year":"2024","journal-title":"BMJ Open Respir Res"},{"key":"2025120415090434000_15.10.e100894.26","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210394"},{"key":"2025120415090434000_15.10.e100894.27","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/aje\/kwab263","article-title":"Using Negative Control Outcomes and Difference-in-Differences Analysis to Estimate Treatment Effects in an Entirely Treated Cohort: The Effect of Ivacaftor in Cystic Fibrosis","volume":"191","author":"Newsome","year":"2022","journal-title":"Am J Epidemiol"},{"key":"2025120415090434000_15.10.e100894.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409083311003"},{"key":"2025120415090434000_15.10.e100894.29","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00080312"},{"key":"2025120415090434000_15.10.e100894.30","doi-asserted-by":"publisher","DOI":"10.1136\/jech-2022-219267"},{"key":"2025120415090434000_15.10.e100894.31","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwad036"},{"key":"2025120415090434000_15.10.e100894.32","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5446"},{"key":"2025120415090434000_15.10.e100894.33","doi-asserted-by":"crossref","DOI":"10.1002\/pds.5790","article-title":"Clarifying the causal contrast: An empirical example applying the prevalent new user study design","volume":"33","author":"Young","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025120415090434000_15.10.e100894.34","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l5657","article-title":"Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners","volume":"367","author":"Desai","year":"2019","journal-title":"BMJ"},{"key":"2025120415090434000_15.10.e100894.35","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.113.000359"},{"key":"2025120415090434000_15.10.e100894.36","unstructured":"Borgan \u00d8 . Aalen-johansen estimator. Wiley statsref: statistics reference, Available: https:\/\/onlinelibrary.wiley.com\/doi\/book\/10.1002\/9781118445112"},{"key":"2025120415090434000_15.10.e100894.37","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwn164"},{"key":"2025120415090434000_15.10.e100894.38","doi-asserted-by":"publisher","DOI":"10.1093\/IJE\/DYAA260"},{"key":"2025120415090434000_15.10.e100894.39","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-023-01906-8","article-title":"Quantitative bias analysis in practice: review of software for regression with unmeasured confounding","volume":"23","author":"Kawabata","year":"2023","journal-title":"BMC Med Res Methodol"},{"key":"2025120415090434000_15.10.e100894.40","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4067"},{"key":"2025120415090434000_15.10.e100894.41","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2023-220100"},{"key":"2025120415090434000_15.10.e100894.42","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/EDE.0000000000001231","article-title":"Benchmarking Observational Methods by Comparing Randomized Trials and Their Emulations","volume":"31","author":"Dahabreh","year":"2020","journal-title":"Epidemiology (Sunnyvale)"},{"key":"2025120415090434000_15.10.e100894.43","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/EDE.0000000000001230","article-title":"Reweighting Oranges to Apples: Transported RE-LY Trial Versus Nonexperimental Effect Estimates of Anticoagulation in Atrial Fibrillation","volume":"31","author":"Webster-Clark","year":"2020","journal-title":"Epidemiology"},{"key":"2025120415090434000_15.10.e100894.44","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwz100"},{"key":"2025120415090434000_15.10.e100894.45","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.4221"},{"key":"2025120415090434000_15.10.e100894.46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17670-8"},{"key":"2025120415090434000_15.10.e100894.47","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21442"},{"key":"2025120415090434000_15.10.e100894.48","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwac098"},{"key":"2025120415090434000_15.10.e100894.49","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/aje\/kwae317","article-title":"Improving the validity of noninterventional comparative effectiveness research by basing study design on a specified existing randomized controlled trial","volume":"194","author":"Wing","year":"2024","journal-title":"Am J Epidemiol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-100894","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T23:16:19Z","timestamp":1764890179000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-100894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":49,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,29]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/bmjopen-2025-100894"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-100894","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}